HALO icon

Halozyme

50.23 USD
-16.35
24.56%
At close May 13, 4:00 PM EDT
Pre-market
50.36
+0.13
0.26%
1 day
-24.56%
5 days
-21.13%
1 month
-18.18%
3 months
-14.30%
6 months
-14.30%
Year to date
4.62%
1 year
15.18%
5 years
108.08%
10 years
208.92%
 

About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Employees: 350

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

185% more call options, than puts

Call options by funds: $36.9M | Put options by funds: $12.9M

13% more first-time investments, than exits

New positions opened: 90 | Existing positions closed: 80

0% more funds holding

Funds holding: 499 [Q3] → 500 (+1) [Q4]

3% less repeat investments, than reductions

Existing positions increased: 173 | Existing positions reduced: 178

1.3% less ownership

Funds ownership: 97.95% [Q3] → 96.65% (-1.3%) [Q4]

17% less capital invested

Capital invested by funds: $7.1B [Q3] → $5.86B (-$1.24B) [Q4]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 4 (-1) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$47
6%
downside
Avg. target
$63
26%
upside
High target
$75
49%
upside

5 analyst ratings

positive
40%
neutral
40%
negative
20%
Leerink Partners
6%downside
$47
Underperform
Downgraded
13 May 2025
Wells Fargo
Mohit Bansal
30% 1-year accuracy
8 / 27 met price target
29%upside
$65
Equal-Weight
Maintained
7 May 2025
HC Wainwright & Co.
Mitchell Kapoor
34% 1-year accuracy
60 / 174 met price target
43%upside
$72
Buy
Reiterated
25 Apr 2025
JP Morgan
Jessica Fye
49% 1-year accuracy
20 / 41 met price target
15%upside
$58
Neutral
Maintained
21 Apr 2025
Benchmark
Robert Wasserman
33% 1-year accuracy
13 / 40 met price target
49%upside
$75
Buy
Reiterated
20 Feb 2025

Financial journalist opinion

Based on 19 articles about HALO published over the past 30 days

Positive
Zacks Investment Research
19 hours ago
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
Neutral
Investors Business Daily
20 hours ago
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use its additive product.
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
Positive
Zacks Investment Research
1 day ago
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Positive
Zacks Investment Research
1 day ago
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Positive
Seeking Alpha
1 day ago
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat
Halozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key growth drivers include the ENHANZE portfolio with new blockbuster drugs, a robust clinical pipeline, and next-gen delivery systems, ensuring sustained royalty growth and competitive advantage. Despite potential risks like the Keytruda SC litigation and pharma tariffs, Halozyme's strong balance sheet, rising free cash flow, and share buybacks boost EPS and shareholder value.
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat
Positive
Investors Business Daily
3 days ago
S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points
Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist.
S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points
Positive
Zacks Investment Research
4 days ago
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
Positive
Zacks Investment Research
5 days ago
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Positive
Zacks Investment Research
6 days ago
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025.
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
Positive
Zacks Investment Research
1 week ago
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Charts implemented using Lightweight Charts™